ANNA LA SALVIA

Dr. ANNA LA SALVIA

FARVA, Istituto Superiore di Sanità, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
ASANNA LA SALVIA
ANNA LA SALVIA
RMRoberta Modica
Roberta Modica
Roberta Elisa RossiRoberta Elisa Rossi
Roberta Elisa Rossi
FSFrancesca Spada
Francesca Spada
MRM. Rinzivillo
M. Rinzivillo
NFNicola Fazio
Nicola Fazio

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
MRMaria Lucia Reale
Maria Lucia Reale
ELEmmanuele De Luca
Emmanuele De Luca
PLPasquale Lombardi
Pasquale Lombardi
LMLaura Marandino
Laura Marandino
CZClizia Zichi
Clizia Zichi
Massimo Di MaioMassimo Di Maio
Massimo Di Maio

2 November 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
RMRoberta Modica
Roberta Modica
ASANNA LA SALVIA
ANNA LA SALVIA
ALAlessia Liccardi
Alessia Liccardi
GCGiuseppe Cannavale
Giuseppe Cannavale
RMRoberto Minotta
Roberto Minotta
Annamaria ColaoAnnamaria Colao
Annamaria Colao
Lipid metabolism is known to be involved in tumorigenesis and disease progression in many common cancer types, including colon, lung, breast and prostate, through modifications of lipid synthesis, storage and catabolism. Furthermore, lipid alterations may arise as a consequence of cancer treatment and may have a role in treatment resistance. Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with increasing incidence, whose mechanisms of cancer initiation and progression are far from being fully understood. Alterations of lipid metabolism may be common across various cancer types, but data about NENs are scattered and heterogeneous. Herein, we provide an overview of the relevant literature on lipid metabolism and alterations in NENs. The available evidence both in basic and clinical research about lipid metabolism in NENs, including therapeutic effects on lipid homeostasis, are summarized. Additionally, the potential of targeting the lipid profile in NEN therapy is also discussed, and areas for further research are proposed.

5 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MRMaria Carmen Riesco-Martínez
Maria Carmen Riesco-Martínez
CFCarlos Fernandez-Martos
Carlos Fernandez-Martos
CGCristina Gravalos-Castro
Cristina Gravalos-Castro
PEPaula Espinosa-Olarte
Paula Espinosa-Olarte
ASANNA LA SALVIA
ANNA LA SALVIA
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
Multimodality treatment is a standard of care for LARC, but the optimal sequencing of the treatment modalities remains unclear. Several randomized clinical trials (RCTs) compared total neoadjuvant treatment (TNT) vs. standard neoadjuvant chemoradiotherapy (CRT) with inconsistent results. A systematic review and meta-analysis was performed to evaluate the efficacy of TNT in terms of complete pathological response (pCR) rate, disease-free and overall survival vs. standard CRT in LARC. A systematic search was performed through MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and meeting abstracts up to May 2020. RCTs comparing CRT vs. TNT followed by surgery in LARC were eligible for the study. Study selection and data extraction were done following PRISMA guidelines by two independent reviewers. The Mantel–Haenzel method was used to obtain a fixed-effects model of pooled odds or hazard ratios for the main outcomes. Eight RCTs, including 2301 patients, met the eligibility criteria. TNT significantly improved pCR rate (OR = 1.99, 95% confidence interval (CI) 1.59–2.49; p < 0.001), 3-year disease-free-survival (DFS) (HR = 0.82, 95%CI 0.71–0.95; p = 0.01) and 3-year overall survival (OS) (hazard ratio (HR) = 0.81, p = 0.04). Grade 3–4 adverse events were not significantly different in both strategies (OR = 1.58; p = 0.14). An improved pCR rate was documented regardless of the type of radiotherapy administered (long vs. short fractionation schedules). No significant heterogeneity was found. The results of this meta-analysis show that TNT improves pCR and survival rates vs. standard preoperative CRT in patients with LARC. TNT may become a new standard of care in LARC, although longer follow-up is needed to properly assess its long-term impact on survival.

11 April 2021 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
PEPaula Espinosa-Olarte
Paula Espinosa-Olarte
ASANNA LA SALVIA
ANNA LA SALVIA
MRMaria C. Riesco-Martinez
Maria C. Riesco-Martinez
BABEATRIZ Anton-Pascual
BEATRIZ Anton-Pascual
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
Neuroendocrine neoplasms (NENs) comprise a broad spectrum of tumors with widely variable biological and clinical behavior. Primary tumor site, extent of disease, tumor differentiation and expression of so matostatin receptors, proliferation and growth rates are the major prognostic factors that determine the therapeutic strategy. Treatment options for advanced disease have considerably expanded in recent years, particularly for well differentiated tumors (NETs). Novel drugs approved over the past decade in this context include somatostatin analogues and 177Lu-oxodotreotide for somatostatin-receptor-positive gastroenteropancreatic (GEP) NETs, sunitinib for pancreatic NETs (P-NETs), and everolimus for P-NETs and non-functioning lung or gastrointestinal NETs. Nevertheless, chemotherapy remains an essential component of the treatment armamentarium of patients with NENs, particularly of patients with P-NETs or those with bulky, symptomatic or rapidly progressive tumors (generally G3 or high-G2 NENs). In this manuscript we will comprehensively review available evidence related to the use of chemotherapy in lung and GEP NENs and will critically discuss its role in the treatment algorithm of this family of neoplasms.